Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Trial protocol design stories

Jul 9, 2026

AstraZeneca and Ionis' heart disease drug Wainua fails pivotal trial, shares plunge

AstraZeneca's shares fell as much as 9% after Wainua, a drug developed with Ionis Pharmaceuticals, unexpectedly failed to meet its primary endpoint in a late-stage trial for ATTR-CM heart disease. The failure has raised concerns about the company's trial design and shaken investor confidence.

Jul 9, 2026·4 sources
00

Top claims

  • ▪AstraZeneca's London-listed shares fell as much as 9% on July 9, 2026, wiping out £23.3 billion in market value at the day's low
  • ▪Jefferies analysts noted that the trial failure could cause a credibility loss for AstraZeneca management, who had expressed strong confidence in the trial's success
  • ▪Wainua's failure leaves Alnylam Pharmaceuticals' Amvuttra as the only approved silencer drug in the transthyretin-mediated amyloid cardiomyopathy market

Subtopics

Clinical Trial Design & Evaluation1Drug Approval and Clinical Trials1Drug Policy, Pricing & Approval1Pharma1

Related timelines

Iran War

209 stories

Russia-Ukraine war

136 stories

Strait of Hormuz blockage

148 stories

Trump administration

161 stories

Congress

110 stories